Effect of SGLT2 inhibitors on microscopic hematuria in IgA nephropathy: a review from the perspective of disease activity biomarkers

To identify the effect of SGLT2 inhibitors on microscopic hematuria in patients with IgA nephropathy (IgAN) and to explore the mechanisms involved.

Microscopic hematuria is an independent predictor of disease progression in IgAN.
SGLT2 inhibitors have shown efficacy in reducing proteinuria and slowing kidney function decline in IgAN.
Existing clinical trials have primarily focused on proteinuria and eGFR, neglecting the impact on hematuria.
Only one observational study has reported a significant reduction in hematuria after SGLT2 inhibitor therapy.

Limited clinical evidence specifically addressing the impact of SGLT2 inhibitors on hematuria.
Hematuria has not been systematically evaluated as an outcome measure in existing trials.

The effect of SGLT2 inhibitors on hematuria in IgAN requires further investigation.